The 100 most influential manuscripts in gastric cancer: A bibliometric analysis

International Journal of Surgery

Volumn 28, Issue , 2016, Pages 83-90

  Powell, Arfon G M T ^a,b   Hughes, Daniel L ^b   Wheat, Jennifer R ^b   Lewis, Wyn G ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Bibliometric analysis; Citations; Gastric cancer

Indexed keywords

BIBLIOMETRICS; CANCER PATIENT; CANCER RESEARCH; GASTROSCOPY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; STOMACH CARCINOMA; UNITED STATES; WEB OF SCIENCE; PATHOLOGY; STOMACH NEOPLASMS;

BIBLIOMETRICS; HUMANS; STOMACH NEOPLASMS;

EID: 84959304088     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2016.02.028     Document Type: Review

References (107)

1. Murray M.R., Wang T., Schroeder G.D., et al. The 100 most cited spine articles. Eur. Spine J. 2012, 21:2059-2069.
2. Kelly J.C., Glynn R.W., O'Briain D.E., et al. The 100 classic papers of orthopaedic surgery: a bibliometric analysis. J. Bone Jt. Surg. Br. 2010, 92:1338-1343.
3. Loonen M.P., Hage J.J., Kon M. Plastic Surgery Classics: characteristics of 50 top-cited articles in four Plastic Surgery Journals since 1946. Plast. Reconstr. Surg. 2008, 121:320e-327e.
4. Paladugu R., Schein M., Gardezi S., et al. One hundred citation classics in general surgical journals. World J. Surg. 2002, 26:1099-1105.
5. Tas F. An analysis of the most-cited research papers on oncology: which journals have they been published in?. Tumour Biol. 2014, 35:4645-4649.
6. Parsonnet J., Friedman G., Vandersteen D., et al. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 1991, 325:1127-1131.
7. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001, 345:784-789.
8. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-first American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992, 52:6735-6740.
9. Nomura A., Stemmermann G.N., Chyou P.H., et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N. Engl. J. Med. 1991, 325:1132-1136.
10. El-Omar E.M., Carrington M., Chow W.H., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404:398-402.
11. Devesa S.S., Blot W.J., Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049-2053.
12. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
13. Forman D., Newell D.G., Fullerton F., et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991, 302:1302-1305.
14. Bonenkamp J.J., Hermans J., Sasako M., et al. Extended lymph-node dissection for gastric cancer. N. Engl. J. Med. 1999, 340:908-914.
15. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
16. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 2007, 357:1810-1820.
17. Ono H., Kondo H., Gotoda T., et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001, 48:225-229.
18. Houghton J., Stoicov C., Nomura S., et al. Gastric cancer originating from bone marrow-derived cells. Science 2004, 306:1568-1571.
19. Li Q.L., Ito K., Sakakura C., et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002, 109:113-124.
20. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br. J. Cancer 1999, 79:1522-1530.
21. Crew K.D., Neugut A.I. Epidemiology of gastric cancer. World J. Gastroenterol. 2006, 12:354-362.
22. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 2006, 24:4991-4997.
23. Forman D., Coleman M., Debacker, et al. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 1993, 341:1359-1362.
24. Ristimäki A., Honkanen N., Jänkälä H., et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997, 57:1276-1280.
25. Siewert J.R., Böttcher K., Stein H.J., et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann. Surg. 1998, 228:449-461.
26. Watanabe T., Tada M., Nagai H., et al. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 1998, 115:642-648.
27. Wong B.C., Lam S.K., Wong W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004, 291:187-194.
28. Bonenkamp J.J., Songun I., Hermans J., et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995, 345:745-748.
29. Becker K.F., Atkinson M.J., Reich U., et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994, 54:3845-3852.
30. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008, 9:215-221.
31. Parsonnet J., Friedman G.D., Orentreich N., et al. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997, 3:297-301.
32. Maeda K., Chung Y.S., Ogawa Y., et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77:858-863.
33. Cuschieri A., Fayers P., Fielding J., et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996, 347:995-999.
34. Huang J.Q., Sridhar S., Chen Y., et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998, 114:1169-1179.
35. El-Omar E.M., Rabkin C.S., Gammon M.D., et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003, 124:1193-1201.
36. Howson C.P., Hiyama T., Wynder E.L. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol. Rev. 1986, 8:1-27.
37. Wagner A.D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 2006, 24:2903-2909.
38. Lu C.D., Altieri D.C., Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998, 58:1808-1812.
39. Pyrhönen S., Kuitunen T., Nyandoto P., et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 1995, 71:587-591.
40. Mirvish S.S. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer 1995, 93:17-48.
41. Han H.J., Yanagisawa A., Kato Y., et al. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res. 1993, 53:5087-5089.
42. Petrocca F., Visone R., Onelli M.R., et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008, 13:272-286.
43. Hiyama E.1, Yokoyama T., Tatsumoto N., et al. Telomerase activity in gastric cancer. Cancer Res. 1995, 55:3258-3262.
44. Fuchs C.S., Mayer R.J. Gastric Carcinoma. N. Engl. J. Med. 1995, 333:32-41.
45. Hartgrink H.H., van de Velde C.J., Putter H., et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol. 2004, 22:2069-2077.
46. Aird I., Bentall H.H., Fraser Roberts J.A. Relationship Between Cancer of Stomach and the ABO Blood Groups. BMJ 1953, 1:799-801.
47. Murad A.M., Santiago F.F., Petroianu A., et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72:37-41.
48. Glimelius B., Ekström K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 1997, 8:163-168.
49. Wanebo H.J., Kennedy B.J., Chmiel J., et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann. Surg. 1993, 218:583-592.
50. Sakata Y., Ohtsu A., Horikoshi N., et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer 1998, 34:1715-1720.
51. Huscher C.G., Mingoli A., Sgarzini G., et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann. Surg. 2005, 241:232-237.
52. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001, 49:347-353. Helicobacter and Cancer Collaborative Group.
53. Myeroff L.L., Parsons R., Kim S.J., et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995, 55:5545-5547.
54. Ming S.C. Gastric carcinoma. A pathobiological classification. Cancer 1977, 39:2475-2485.
55. Nomura A.M., Stemmermann G.N., Chyou P.H. Gastric cancer among the Japanese in Hawaii. Jpn. J. Cancer Res. 1995, 86:916-923.
56. Park K., Kim S.J., Bang Y.J., et al. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc. Natl. Acad. Sci. U. S. A. 1994, 13(91):8772-8776.
57. Kelley J.R., Duggan J.M. Gastric cancer epidemiology and risk factors. J. Clin. Epidemiol. 2003, 56:1-9.
58. Toyota M., Ahuja N., Suzuki H., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999, 59:5438-5442.
59. Siewert J.R., Böttcher K., Roder J.D., et al. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br. J. Surg. 1993, 80:1015-1018.
60. Mayer B., Johnson J.P., Leitl F., et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 1993, 53:1690-1695.
61. Hansson L.E., Nyrén O., Hsing A.W., et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N. Engl. J. Med. 1996, 335:242-249.
62. Hohenberger P., Gretschel S. Gastric cancer. Lancet 2003, 362:305-315.
63. Rosivatz E., Becker I., Specht K., et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am. J. Pathol. 2002, 161:1881-1891.
64. Yasumoto K., Okamoto S., Mukaida N., et al. Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene. J. Biol. Chem. 1992, 267:22506-22511.
65. Figueiredo C., Machado J.C., Pharoah P., et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J. Natl. Cancer Inst. 2002, 94:1680-1687.
66. Morson B.C. Carcinoma Arising from Areas of Intestinal Metaplasia in the Gastric Mucosa. Br. J. Cancer 1955, 9:377-385.
67. Yoo C.H., Noh S.H., Shin D.W., et al. Recurrence following curative resection for gastric carcinoma. Br. J. Surg. 2000, 87:236-242.
68. Uemura N., Mukai T., Okamoto S., et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1997, 6:639-642.
69. Japanese Gastric Cancer Association Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011, 14:101-112.
70. Fukase K., Kato M., Kikuchi S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008, 372:392-397.
71. Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011, 14:113-123.
72. Hofmann M., Stoss O., Shi D., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805.
73. Xia L., Zhang D., Du R., et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123:372-379.
74. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002, 5:1-5.
75. Hundahl S.A., Phillips J.L., Menck H.R. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000, 88:921-932.
76. Wang T.C., Dangler C.A., Chen D., et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000, 118:36-47.
77. Correa P., Fox J., Fontham E., et al. Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer 1990, 66:2569-2574.
78. Dent D.M., Madden M.V., Price S.K. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br. J. Surg. 1988, 75:110-112.
79. Songun I., Putter H., Kranenbarg E.M., et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010, 11:439-449.
80. Sasako M., Sano T., Yamamoto S., et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N. Engl. J. Med. 2008, 359:453-462.
81. Machado J.C., Figueiredo C., Canedo P., et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003, 125:364-371.
82. Shimoyama Y., Hirohashi S. Expression of E- and P-cadherin in gastric carcinomas. Cancer Res. 1991, 51:2185-2192.
83. Farrow D.C., Vaughan T.L., Hansten P.D., et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1998, 7:97-102.
84. Vaughan T.L., Davis S., Kristal A., et al. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 1995, 4:85-92.
85. Martin H.M., Filipe M.I., Morris R.W., et al. p53 expression and prognosis in gastric carcinoma. Int. J. Cancer 1992, 50:859-862.
86. Machado J.C., Pharoah P., Sousa S., et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001, 121:823-829.
87. Maruyama K., Gunvén P., Okabayashi K., et al. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann. Surg. 1989, 210:596-602.
88. Yang L. Incidence and mortality of gastric cancer in China. World J. Gastroenterol. 2006, 12:17-20.
89. Sakamoto H., Mori M., Taira M., et al. Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:3997-4001.
90. Ichihara F., Kono K., Takahashi A., et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 2003, 9:4404-4408.
91. Oka S., Tanaka S., Kaneko I., et al. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest. Endosc. 2006, 64:877-883.
92. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 2008, 19:1523-1529.
93. Honda S., Fujioka T., Tokieda M., et al. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res. 1998, 58:4255-4259.
94. Ernst P.B., Gold B.D. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu. Rev. Microbiol. 2000, 54:615-640.
95. Earle C.C., Maroun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur. J. Cancer 1999, 35:1059-1064.
96. Noguchi Y., Imada T., Matsumoto A., et al. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer 1989, 64:2053-2062.
97. Tanner M., Hollmén M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005, 16:273-278.
98. Engel L.S., Chow W.H., Vaughan T.L., et al. Population attributable risks of esophageal and gastric cancers. J. Natl. Cancer Inst. 2003, 95:1404-1413.
99. Fleisher A.S., Esteller M., Wang S., et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 1999, 59:1090-1095.
100. Yasui W., Sumiyoshi H., Hata J., et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988, 48:137-141.
101. Imai S., Koizumi S., Sugiura M., et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9131-9135.
102. Yonemura Y., Endo Y., Fujita H., et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin. Cancer Res. 1995, 5:1823-1829.
103. Leung S.Y., Yuen S.T., Chung L.P., et al. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res. 1999, 59:159-164.
104. Takaishi S., Okumura T., Tu S., et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27:1006-1020.
105. Roder J.D., Böttcher K., Siewert J.R., et al. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 1993, 72:2089-2097.
106. Fukushige S., Matsubara K., Yoshida M., et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol. Cell Biol. 1986, 6:955-958.
107. World Health Organisation Stomach Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012 2012, (accessed 01.08.15.). http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp.